Usted buscó: adalimumab (Maltés - Inglés)

ori adalimumab
ris adalimumab

effikaċja ta ’ adalimumab.
ed of adalimumab.

humira 40 mg injezzjoni adalimumab
humira 40 mg injection adalimumab

is-sustanza attiva hi adalimumab.
the active substance is adalimumab.

kunjett wieħed fih 40 mg adalimumab
1 vial containing 40 mg adalimumab

kunjett wieħed ta’ 0.8 mg adalimumab
one 0.8 ml vial contains 40 mg adalimumab

studju sc-ii: abatacept kontra adalimumab
study sc-ii: abatacept versus adalimumab

t aw kunjett wieħed ta ’ 0. 8 mg adalimumab
one 0.8 ml vial contains 40 mg adalimumab

trudexa 40 mg soluzzjoni għall-injezzjoni adalimumab
trudexa 40 mg solution for injection adalimumab

zz trudexa 40 mg soluzzjoni għall- injezzjoni adalimumab
ed trudexa 40 mg solution for injection adalimumab

kunjett wieħed ta’ 0.8 ml li fih 40 mg adalimumab
one 0.8 ml vial contains 40 mg adalimumab

humira 40 mg injezzjoni użu għal taħt il- ġilda adalimumab
humira 40 mg injection subcutaneous use adalimumab

humira huwa mediċina li fiha s-sustanza attiva adalimumab.
humira is a medicine that contains the active substance adalimumab.

is- sustanza attiva, adalimumab, hija anti- korp uman li l
monoclonal antibodies are t

trudexa 40 mg soluzzjoni għall- injezzjoni f’ kunjetti adalimumab
information for the user

minħabba li l- eliminazzjoni ta ’ adalimumab tista ’ tieħu sa me
because the elimination of adalimumab may take up to five months, monitoring should be continued throughout this period. t uc

is-sustanza attiva f’trudexa, adalimumab, hi antikorp monoklonali.
the active substance in trudexa, adalimumab, is a monoclonal antibody.

sterili ta ’ 40 mg adalimumab imdewba f’ soluzzjoni ta ’ 0. 8 ml.
trudexa 40 mg solution for injection in pre-filled syringe is supplied as a sterile solution of 40 mg lon adalimumab dissolved in 0.8 ml solution.

it-teħid ta’ adalimumab waqt it-tqala m’huwiex rrakkomandat.
administration of adalimumab is not recommended during pregnancy.

il- livelli minimali fissi fis- serum ta ’ adalimumab żdiedu bejn wieħed
following subcutaneous administration of 40 mg of humira every other week in adult rheumatoid arthritis (ra) patients the mean steady-state trough concentrations were approximately 5 µg/ ml (without concomitant methotrexate) and 8 to 9 µg/ ml (with concomitant methotrexate), respectively.